Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen)
Übersicht


Zum ersten Bild Abb. 9: Telmisartan - Renoprotektiver Effekt Abb. 10: Telmisartan - LVH Abb. 11: Telmisartan - LVH Abb. 12: Telmisartan - LVH Abb. 13: Telmisartan - LVH Abb. 14: Telmisartan - Arterienelastizität Aktuelles Bild - Abb. 15: Telmisartan - Arterienelastizität Abb. 16: Effekte bei Zielorganschädigung
Abbildung 15: Telmisartan - Arterienelastizität
In this study, 24 patients with hypertension received telmisartan 40 mg/day for 3 months.1 Brachial-ankle pulse wave velocity (ba-PWV) was significantly reduced. Office blood pressure was also reduced. However, the improvement in ba-PWV was greater than predicted on the basis of blood pressure changes. 1. Uchida H, et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
 
Telmisartan - Arterienelastizität
Vorheriges Bild Nächstes Bild   


Abbildung 15: Telmisartan - Arterienelastizität
In this study, 24 patients with hypertension received telmisartan 40 mg/day for 3 months.1 Brachial-ankle pulse wave velocity (ba-PWV) was significantly reduced. Office blood pressure was also reduced. However, the improvement in ba-PWV was greater than predicted on the basis of blood pressure changes. 1. Uchida H, et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung